Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00246129
Recruitment Status : Unknown
Verified May 2008 by Hammersmith Hospitals NHS Trust.
Recruitment status was:  Active, not recruiting
First Posted : October 31, 2005
Last Update Posted : May 12, 2008
Information provided by:
Hammersmith Hospitals NHS Trust

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Unknown
  Estimated Primary Completion Date : April 2009
  Estimated Study Completion Date : April 2011

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 March 22, 2012 April 17, 2012